Back to Agenda
Session 2: Digital Labeling
Session Chair(s)
Rie Matsui, RPh
Senior Director, Regional Labeling Head for APAC, International Labeling
Pfizer R&D Japan G.K., Japan
Kathleen Salazar, MA, MBA
Head, Global Labeling Implementation
Johnson & Johnson Innovative Medicine, United States
Fueled largely by the COVID 19 pandemic, the acceleration and enhancement of digitalization in the pharmaceutical industry has been unprecedented, including digital/electronic labeling. This session will explore the benefits, status, and current developments around digital/electronic labeling for patients and healthcare professionals across regions. This session will include perspectives from regulators and industry representatives and will cover the opportunities and hurdles of introducing digital/electronic labeling.
Learning Objective : At the conclusion of this session, participants should be able to:
- Understand the concept of digital labeling and forms it may take in making product information available to patients and prescribers
- Discuss the advantages of digital/electronic labeling and the benefit to patients and prescribers
- Describe the current environment for digital labeling across regions
Speaker(s)
Electronic Product Information (ePI) Towards Harmonised Implementation in the European Union
Elizabeth Scanlan, PhD, MSc
European Medicines Agency, Netherlands
ePI Product Owner
Speaker
Giovanna Ferrari, PhD
Pfizer Ltd, United Kingdom
Regional Labelling Lead, Senior Director
Where Asia is Right Now
Rie Matsui, RPh
Pfizer R&D Japan G.K., Japan
Senior Director, Regional Labeling Head for APAC, International Labeling
ePI Principle and Set-up Project
Tomoko Ohsawa, PhD
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Director of Office of Informatics and Management for Safety
PharmaLedger ePI
Patrick Maher
Novartis, Switzerland
PharmaLedger ePI use case Co-Lead / Senior Operations Manager SPT/ TEP
Have an account?